PF-Atlas › Clinical Trials › NCT02113397

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

TOBI™ Podhaler™ 112 mg inhaled twice daily · Not specified

Registry ID
NCT02113397
Phase
Not specified
Status
Terminated
Drug / intervention
TOBI™ Podhaler™ 112 mg inhaled twice daily
Sponsor
Dartmouth-Hitchcock Medical Center
Start
2014-04

About this trial

TOBI™ Podhaler™ 112 mg inhaled twice daily is evaluated in NCT02113397, a idiopathic pulmonary fibrosis study sponsored by Dartmouth-Hitchcock Medical Center. Current status: Terminated.

View NCT02113397 on ClinicalTrials.gov →

Explore related

All TOBI™ Podhaler™ 112 mg inhaled twice daily trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02113397 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.